Skip to main content
Premium Trial:

Request an Annual Quote

Accelrys Buys Scynexis' SaaS Platform

NEW YORK (GenomeWeb News) — Accelrys has purchased Scynexis' web-based Hit Explorer Operating System, or HEOS, a product which Accelrys began marketing last October under a reseller agreement as part of its cheminformatics offering.

Combined with its cheminformatics offerings, the HEOS platform enables collaborative drug discovery by providing access to chemical registration, biological assay results, computational and visual analytics, safety assessment and pharmacokinetics data, and other project information in a cloud-based infrastructure, Accelrys said this week.

Accelrys President and CEO Max Carnecchia said in a statement that the firm looks forward to "broadening the applicability and reach of HEOS as a secure, easy-to-use, Cloud-based information management workspace" as many of the company's customers engage in "multi-site [and] multi-collaborator projects."

Accelrys said that its purchase of the HEOS software-as-a service-based system includes software and supporting personnel, but it did not provide additional information. Financial details of the acquisition also were not disclosed.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.